Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 60/100

Entitlement Offer to raise approximately $10 million

Tuesday, October 31, 2023 1 min read
Key Takeaway: Radiopharm Theranostics has announced an entitlement offer to raise around $10 million. This move comes alongside positive clinical updates and the recent approval from the US FDA for a Phase I study targeting B7H3 with Betabart (RV-01). The company is actively advancing its clinical programs, indicating a strong pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Entitlement offer aims to raise approximately $10 million.
  • Positive clinical updates across multiple programs.
  • Recent IND approval from the US FDA for a new therapeutic study.

Full Press Release Details

• Announcements
• Price Sensitive , With Summary , With Video
• October 31, 2023
ANNOUNCEMENT SUMMARY
Loading Viewer…

More Announcements & Updates

• Announcements
• June 20, 2024
• Announcements
• September 30, 2022
• Updates
• January 10, 2025
• Announcements
• January 5, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of Radiopharm's entitlement offer?

The entitlement offer aims to raise approximately $10 million.

What recent FDA approval did Radiopharm receive?

Radiopharm received IND approval from the US FDA for a Phase I study targeting B7H3.

What updates has Radiopharm provided on its clinical programs?

Radiopharm has shared positive clinical updates across four programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics capital raising clinical updates FDA approval BetaBart
Last updated: Oct 31, 2023